NURIX THERAPEUTICS INC. - COMMON STOCK

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

09 7 2025 13:01:00 提供 Nasdaq GlobeNewswire

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

07 7 2025 04:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 6 2025 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

12 6 2025 04:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

06 6 2025 04:00:00 提供 Nasdaq GlobeNewswire

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

02 6 2025 04:00:05 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

28 5 2025 04:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 5 2025 13:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

15 5 2025 04:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

14 5 2025 06:30:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

28 4 2025 13:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

25 4 2025 10:00:00 提供 Nasdaq GlobeNewswire

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

17 4 2025 04:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 4 2025 13:01:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

08 4 2025 13:00:00 提供 Nasdaq GlobeNewswire

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

02 4 2025 04:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

25 3 2025 13:30:00 提供 Nasdaq GlobeNewswire

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

17 3 2025 04:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 3 2025 13:00:00 提供 Nasdaq GlobeNewswire

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

13 3 2025 13:00:00 提供 Nasdaq GlobeNewswire